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Abstract
Rationale:Chronic obstructive pulmonary disease exacerbations are
associated with disease progression, higher healthcare cost, and
increased mortality. Published predictors of future exacerbations
include previous exacerbation, airflow obstruction, poor overall
health, home oxygen use, and gastroesophageal reflux.
Objectives: To determine the value of adding blood biomarkers to
clinical variables to predict exacerbations.
Methods: Subjects from the SPIROMICS (Subpopulations and
Intermediate Outcomes Measures in COPD Study) (n = 1,544) and
COPDGene (Genetic Epidemiology of COPD) (n = 602) cohorts had
90 plasma or serum candidate proteins measured on study entry
usingMyriad-RBMmultiplex panels.We defined total exacerbations
as subject-reportedworsening in respiratory health requiring therapy
with corticosteroids and/or antibiotics, and severe exacerbations as
those leading to hospitalizations or emergency room visits. We
assessed retrospective exacerbations during the 12 months before
enrollment and then documented prospective exacerbations in each
cohort. Exacerbations were modeled for biomarker associations with
negative binomial regression including clinical covariates (age, sex,
percent predicted FEV1, self-reported gastroesophageal reflux,
St. George’s Respiratory Questionnaire score, smoking status). We
used the Stouffer-Liptak test to combine P values for metaanalysis.
Measurements andMainResults:Between the two cohorts, 3,471
total exacerbations (1,044 severe) were reported. We identified
biomarkers within each cohort that were significantly associatedwith
ahistory of exacerbation andwith a future exacerbation, but therewas
minimal replication between the cohorts. Although established
clinical features were predictive of exacerbations, of the blood
biomarkers only decorin and a2-macroglobulin increased predictive
value for future severe exacerbations.
Conclusions: Blood biomarkers were significantly associated with
the occurrence of exacerbations but were not robust between cohorts
and added little to the predictive value of clinical covariates for
exacerbations.
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Chronic obstructive pulmonary disease
(COPD) is a spectrum of lung diseases
characterized by airflow obstruction,
emphysema, and chronic bronchitis. Some
individuals with COPD experience acute
exacerbations of COPD (AECOPD) typified
by increased cough, sputum production,
shortness of breath, and wheezing and are
treated with antibiotics and/or prednisone.
Recent work suggests that there are subsets of
current and former smokers who are more
susceptible to frequent AECOPD (1, 2).
Clinical predictors of AECOPD include
exacerbation during the preceding year,
spirometric airflow obstruction, low
respiratory health scores, and reported
gastroesophageal reflux (1, 3, 4).
However, the sensitivity and specificity
of these clinical predictors is imperfect.
Identifying blood-based biomarkers that
could improve the prediction of AECOPD
is an ongoing research focus that could
potentially deliver precision medicine to this
heterogeneous disease and increase the
efficiency of clinical trials. Susceptible
patients seem to exhibit greater systemic
inflammation, as evidenced by elevated
white blood cell count (1), fibrinogen (5, 6),
IL-6 (7), and C-reactive protein (CRP) (6).
Surfactant protein D, fetuin A, adiponectin,
and CRP are implicated as predictive of
AECOPDs (8–10). The U.S. Food and Drug
Administration recently qualified plasma
fibrinogen as a biomarker, primarily based
on data from ECLIPSE (Evaluation of
COPD Longitudinally to Identify Predictive
Surrogate Endpoints), to enrich clinical
trials for patients likely to have hospitalized
COPD exacerbations (11). Despite these
advances, blood biomarkers have not
achieved widespread use or proven clinical
benefit to predict AECOPD.
SPIROMICS (Subpopulations and
Intermediate Outcomes Measures in
COPD Study) and COPDGene (Genetic
Epidemiology of COPD) are two large,
National Institutes of Health (NIH)-funded
COPD cohorts in which retrospective
exacerbations and peripheral blood for
biomarker studies were collected at study
entry and prospective exacerbations are
being captured. To confirm published
findings and identify novel biomarker
associations with AECOPD, we generated a
custom biomarker panel and evaluated the
ability of measured biomarkers to predict
AECOPD. Considering the cohorts
individually and in a metaanalysis, our
results call into question the reproducibility
and clinical utility of blood biomarkers
measured in the stable state to predict future
COPD exacerbations.
Methods
Study Population
SPIROMICS (ClinicalTrials.gov Identifier:
NCT 01969344) is an ongoing multicenter
prospective observational study funded by
the NIH (12) that enrolled 2,982 subjects
between November 2011 and January 2015.
The institutional review board at all
participating sites approved the study
protocol. Study participants provided written
informed consent. The data reported here
include results from the first 1,544 subjects
enrolled in strata 2–4 (see APPENDIX in the
online supplement for further details) (12, 13).
The NIH sponsored multicenter
COPDGene (ClinicalTrials.gov Identifier:
NCT 01969344) study was approved and
reviewed by the institutional review board
at all participating centers (14). Study
participants provided written informed
consent. In brief, all subjects were between
45 and 80 years old, had at least 10 pack-
years of smoking, and had not had an acute
respiratory exacerbation for at least 30 days
(14, 15). Of the larger cohort of 10,300
subjects, 602 were selected to undergo a
comprehensive biomarker study. For more
details on study population, please see
online supplement APPENDIX.
Biomarker Panel and Data Generation
Based on the literature, we created a custom
panel assay for 119 candidate biomarkers
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At a Glance Summary
Scientific Knowledge on the
Subject: Chronic obstructive
pulmonary disease (COPD) is a
systemic disease, and recent studies
suggest candidate blood biomarkers
(e.g., C-reactive protein, fibrinogen,
blood eosinophils, and white blood cell
count) may be predictive of future
exacerbations. However, few studies
have reported large biomarker panels
in multiple well-characterized COPD
populations that also include smokers
at risk for COPD and longitudinal data.
What This Study Adds to the
Field: This study examined blood
biomarkers predictive of acute
respiratory exacerbations in current
and former smokers with and without
COPD using two large, well-
characterized cohorts, SPIROMICS
(Subpopulations and Intermediate
Outcomes Measures in COPD Study)
and COPDGene (Genetic Epidemiology
of COPD). Although within each cohort
a subset of biomarkers was associated
with the presence of exacerbations
independent of clinical predictors
(respiratory symptoms, airflow
obstruction, gastrointestinal reflux,
smoking status, history of prior
exacerbation), replication of biomarkers
across the two cohorts was poor, and the
increased predictive value of adding
biomarkers to clinical variables was
small. The study highlights the need for
cohort replication and improved
understanding of COPD exacerbations.
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using 13 Myriad-RBM (Austin, TX)
multiplex assays (see Table E1 in the online
supplement). Biomarkers were selected
based on known or putative links to COPD;
details of assay characteristics regarding
coefficient of variation, detection range, and
reliability estimates are described in a
SPIROMICS pilot study (16) and a
COPDGene study of emphysema (17), with
additional details given by Sun and
colleagues (18). All measurements used in
this study were performed on a single blood
sample collected at baseline. SPIROMICS
also included a smaller study embedded in
the larger study that used replicate samples
collected at a separate visit to evaluate assay
performance (Table E1).
Of the 119 measured biomarkers, 90
had values from at least 90% of subjects
above the lower limit of quantitation
(LLOQ) in both cohorts, and these form the
basis of this analysis. One biomarker
(prostate-specific antigen, free) was
removed because it was only expressed
in men.
Clinical Data and Definitions
Full details about COPDGene and
SPIROMICS and the collection of clinical
data has been described (12, 14). In both
cohorts, COPD was defined as post-
bronchodilator ratio of FEV1 to FVC less
than 0.70. We used Global Initiative for
Chronic Obstructive Lung Disease (GOLD)
guidelines (19) to assess COPD severity as
GOLD stage 1–4. Current or ex-smokers at
risk for COPD but without spirometric
evidence of airflow obstruction (FEV1/FVC
>0.70) were classified as GOLD stage 0.
Subjects with FEV1/FVC greater than or
equal to 0.70 and FEV1 less than 80% were
classified as preserved ratio impaired
spirometry (20). Both studies used the
St. George’s Respiratory Questionnaire
(SGRQ) to capture respiratory symptoms
(21). Chronic bronchitis was defined in the
COPDGene cohort as affirming either
having chronic cough or phlegm
production more than 3 months/yr for 2 or
more consecutive years (22). Chronic
bronchitis was defined in the SPIROMICS
study by similar criteria. Volumetric
computed tomography scans were acquired
in both cohorts (see APPENDIX in the online
supplement for further details related to
clinical phenotyping) (14).
Acute exacerbations of respiratory
disease were ascertained for the year prior at
time of study entry; these were defined as
retrospective exacerbations, and blood was
drawn at this time. Prospective
exacerbations were then monitored during
the longitudinal follow-up visits; these
encounters were scheduled every 6 months
in COPDGene and every 3 months in
SPIROMICS. An exacerbation was recorded
when a patient reported a worsening of their
respiratory status and were treated with
antibiotics and/or systemic steroids for the
episode irrespective of their treatment
location. The total number of exacerbations
was the total number of these events
reported. A severe exacerbation was a report
of visiting an emergency room and/or
hospitalization for an acute episode of
respiratory disease.
Statistical Analysis
Biomarker values were transformed
individually for each study using empirical
quantile normalization as described (18).
No analysis was conducted on analytes with
greater than 90% of measurements less than
LLOQ (Table E1). Linear regression models
were conducted on analytes in which less
than 10% of measurements were less than
LLOQ. Logistic regression was conducted
on for analytes with 10–90% of values less
than LLOQ. Values below the LLOQ were
imputed to half the LLOQ. The very small
number (,0.1%) of measurements above
the detection range of the assay was set at
the highest detected value for analysis.
Analyses were conducted using R (23).
Exacerbations in the year before enrollment
(retrospective) and during longitudinal follow-
up (prospective) were modeled with a negative
binomial regression with offset for exposure
time and a zero inflation model to account for
the excess number of subjects who reported no
acute episodes of respiratory disease.
Associations of exacerbations to biomarkers
were first determined without covariates.
Then, this model was applied separately to the
subjects in the two study populations described
previously for both COPDGene and
SPIROMICS with the clinical covariates of age,
sex, percent-predicted FEV1, self-report of
gastroesophageal reflux, SGRQ, smoking
status, and biomarker batch analysis (for
SPIROMICS only). The zero-inflation
component of the model included the clinical
covariate percent-predicted FEV1 only. Clinical
covariates were selected after reviewing the
current literature on exacerbations; only
clinical covariates that were significant in
several cohort studies were used.
For each biomarker, the model fitting
returns an estimate, SE, and P value for the
association of the biomarker within the
count model (negative binomial) and an
estimate for the association of the
biomarker for zero counts within the zero-
inflated component of the model (gamma
parameter) (24, 25). The P values were
adjusted for multiple testing using the
Benjamini-Hochberg method and false
discovery rate (FDR) values less than 0.05
were considered significant. The Stouffer-
Liptak test was used to combine the
P values from each cohort for the
metaanalysis. Prospective exacerbations
were modeled using the same negative
binomial regression offset for time and a
zero inflation model; the same clinical
covariates were used as in the retrospective
analysis with the addition of adjusting for
history of prior exacerbation.
Cox proportional hazards multiple
regression were used to determine hazard
ratios for time to first episode on significant
biomarkers identified in the prospective
analysis (26, 27). For the proportional
hazards model, the clinical covariates from
the negative binomial regression were used
with the addition of history of exacerbation.
To estimate the effect size for the clinical
predictors and biomarkers the Cragg and
Uhler pseudo R-squared method was used on
the zero-inflated negative binomial model (28).
A stepwise multinomial regression
using significant univariate clinical factors
and biomarkers was performed on both
cohorts to assess for reproducibility between
the cohorts (see APPENDIX in the online
supplement).
Results
Study Population
Demographics, physiology, healthscores,
and quantitative computed tomography
measurements for emphysema are listed in
Table 1 for both cohorts. The cohorts were
similar in many aspects, including age at
enrollment, body mass index, pack-years of
smoking history, and chronic bronchitis
history (Table 1), with notable differences.
SPIROMICS subjects were more likely to
report being current smokers, were less
likely to be non-Hispanic white, exhibited
less airflow obstruction, but a greater
bronchodilator response, higher SGRQ
total score, lower BODE index, and higher
resting oxygen saturation (all comparisons,
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P, 0.001). These differences are reflected
in the higher percentage of subjects in
SPIROMICS with mild COPD (GOLD
stage 1) compared with COPDGene
(16.9 vs. 1.2%, respectively).
SPIROMICS subjects were followed for
2.286 0.8 years (mean6 SD), whereas the
COPDGene cohort was followed for 4.046
1.1 years. At baseline, the total retrospective
exacerbation rate was slightly lower in
SPIROMICS subjects, likely reflecting a greater
fraction of subjects with less severe disease, but
the rate of severe retrospective exacerbations
was similar between cohorts (Table 2). Overall,
SPIROMICS had a lower prospective
exacerbation rate, but this finding varied across
GOLD stages. Rates of severe prospective
exacerbations were also lower in SPIROMICS.
Biomarker Associations
We performed separate extensive analyses
for both cohorts, and a metaanalysis
(Supplemental File E1). These biomarker
analyses were conducted on total and severe for
both retrospective and prospective
exacerbations, with and without clinical
covariates on all subjects (Supplemental File E1,
Tabs E1–E8). The analysis was repeated on a
subset consisting of GOLD stage 2–4 subjects
(Supplemental File E1, Tabs E9–E12). In most
analyses, a small percentage of biomarkers
were significant in each cohort. However,
rarely were biomarkers significant in the
metaanalyses. It became obvious that,
regardless the type of exacerbation or
population, results in one cohort were not
reflected well in the other cohort. In most
cases, inclusion of clinical covariates in the
models further reduced the number of
significant findings (e.g., for all prospective
exacerbations with vs. without covariates)
(Figure 1). As expected, clinical features were
individually significant in both cohorts for
predicting exacerbations as exemplified by the
analysis for total prospective exacerbations
(Table E2).
Blood Biomarkers Associated with
Total and Severe Retrospective
Exacerbation
Without including any clinical covariates,
only one biomarker was significantly
associated with a history of severe
retrospective exacerbation. a1-Antitrypsin
(A1AT; SERPINA1) was statistically
significant in both the COPDGene cohort and
in the metaanalysis, but not in the SPIROMICS
cohort (Supplemental File E1, Tabs E9 and
E10). When including clinical covariates, no
biomarkers were significantly associated with
total retrospective exacerbations in the
SPIROMICS cohort or the metaanalysis, but
two biomarkers were significant in COPDGene
(Table E3 and Supplemental File E1, Tab 1).
When considering only severe retrospective
exacerbations, we found four statistically
significant biomarkers in SPIROMICS and two
in COPDGene (Table E4). Only one of these
biomarkers was significant in both cohorts
(ICAM1), but was not significant in the
metaanalysis (Supplemental File E1, Tab E2).
In subjects with more severe COPD
(GOLD stages 2–4), no biomarkers in either
cohort were significantly associated with
total retrospective exacerbations (Table E5).
In this subgroup, we did identify significant
associations with severe exacerbations in
the COPDGene cohort for five biomarkers
Table 1. Characteristics of Cohorts
COPDGene
(n = 602)
SPIROMICS
(n = 1,544) P Value
Age at enrollment, yr 63.6 (8.6) 64.5 (8.8) 0.03
BMI 28.3 (5.5) 27.9 (5.3) 0.13
Male,% 51 55 0.12
Current smoker, % 25 38 ,0.001
ATS pack-years 47.4 (26.7) 49.9 (23.6) 0.04
FEV1 2.0 (1.0) 3.4 (1.0) ,0.001
FEV1% predicted 68 (30) 73 (26) ,0.001
FEV1/FVC 58 (20) 62 (16) ,0.001
Change in FEV1 with bronchodilators, % 7.3 (10) 13.6 (13) ,0.001
Emphysema, %* 9.5 (11.7) 8.1 (10.1) 0.01
SGRQ 28.2 (23.2) 32.0 (19.9) ,0.001
BODE 1.8 (2.1) 1.4 (1.9) ,0.001
SpO2, resting 93.9 (3.7) 95.5 (2.8) ,0.001
Chronic bronchitis, % 19 20 0.43
Duration of follow-up, yr 4.0 (1.1) 2.3 (0.8)
PRISm 1.5 N/A
Healthy smokers 39.5 31.6
GOLD stage, %
Stage 1 1.2 16.9
Stage 2 24.2 29.5
Stage 3 21.5 16.1
Stage 4 12.1 5.9
Subjects with exacerbation in prior year, % 30 24 ,0.001
Subjects with severe exacerbation in prior year, % 11 11 0.47
Definition of abbreviations: ATS = American Thoracic Society; BMI = body mass index; BODE = BMI, airflow obstruction, dyspnea, and exercise index (42);
COPDGene = Genetic Epidemiology of COPD; GOLD =Global Initiative for Chronic Obstructive Lung Disease; N/A = not applicable; PRISm= preserved
ratio, impaired spirometry; SGRQ= St. George’s Respiratory Questionnaire; SPIROMICS = Subpopulations and Intermediate Outcomes Measures in
COPD Study; SpO2 = oxygen saturation as measured by pulse.
PRISm: FEV1/FVC .0.7; FEV1 ,80%.
Data are shown as mean (SD) unless otherwise indicated.
*% Emphysema defined as 2950 HU.
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(sRAGE, brain-derived neurotrophic factor,
plasminogen activator inhibitor-1, CXCL5,
and A1AT) (Table E6), but none were
significant within the SPIROMICS cohort.
In the metaanalysis, six biomarkers were
significantly associated with severe
retrospective exacerbations (Supplemental
File E1, Tab E6).
Biomarkers Predictive of Future
Exacerbations
The two cohorts yielded a robust amount of
follow-up data to permit association of
baseline biomarker values to future
exacerbations: 3,653 person-years in
SPIROMICS and 2,739 person-years in
COPDGene. Moreover, a substantial
fraction of our subjects had exacerbations.
Collectively, 58.2% of subjects with COPD
and 19.4% of smokers without airflow
obstruction reported at least one respiratory
event requiring antibiotics and/or
prednisone during the follow-up period, and
29.9% of subjects with COPD and 6.8% of
smokers without airflow obstruction
reported a severe exacerbation.
Without clinical covariates in the
model, the COPDGene cohort identified
multiple associations of baseline biomarkers
with future exacerbations (19 with total, 13
with severe) (Supplemental File E1, Tabs
E11 and E12), whereas the SPIROMICS
cohort found two biomarkers each
associated with total exacerbations and
severe exacerbations (Supplemental File E1,
Tabs E11 and E12). Once again, however,
when including clinical variables in the
prediction model, no baseline biomarkers
significantly associated with future total or
severe exacerbations in prospective follow-
up (Table E7 and Supplemental File E1, Tab
E3). In the metaanalysis, two biomarkers
were associated with prospective severe
exacerbations; one in COPDGene, and none
in the SPIROMICS cohort (Table 3 and
Supplemental File E1, Tab E4). Of these,
only decorin (DCN) was significant in both
COPDGene and the metaanalysis (FDR =
0.001; P, 0.001). a2-Macroglobulin
(A2M) (FDR = 0.011; P, 0.001) was
significant only in the metaanalysis.
In subjects with more severe COPD
(GOLD stages 2–4), none of the biomarkers
were significantly associated with future
total exacerbations (Table E8). When
looking only at severe exacerbations, DCN
(FDR = 0.015; P, 0.001) remained
positively associated with severe
exacerbations both in the COPDGene
cohort and in the metaanalysis (Table 4).
By contrast, the SPIROMICS cohort
identified associations of future severe
exacerbations with five biomarkers: A1AT
and ferritin (both FDR = 0.010; P, 0.001),
CXCL10 and CXCL9 (both FDR = 0.028;
P, 0.001), and CCL11 (FDR = 0.028;
P, 0.002).
A Cox proportional hazards model was
used to assess associations between
biomarkers and time-to-next exacerbation.
In this model, none of the adjusted hazards
ratios differed significantly from 1 in both
cohorts for total exacerbations. sRAGE
trended toward a significant association in
SPIROMICS for severe exacerbations, but
these results were not replicated in COPDGene
(APPENDIX in the online supplement, Figure
E2, and Tables E9 and E10).
To estimate the effect size for each
biomarker, we calculated a pseudo R2 value
to determine whether each biomarker
improved the ability to detect the outcome
when compared with clinical covariates.
Clinical predictors accounted for the
majority of variability seen in our model,
but some of the biomarkers did marginally
improve (additional 1–2%) the model’s
ability to predict the next exacerbation
above clinical covariates alone (Tables
E11–E14).
To evaluate the possibility that a panel
of biomarkers may be more predictive than
individual biomarkers across the two
studies, stepwise multinomial regression
was performed for each cohort using
significant univariate factors for total severe
prospective exacerbations. These analyses
demonstrated that clinical predictors were
relatively preserved between cohorts,
whereas with the exception of A1AT,
biomarkers did not replicate (Tables E15
and E16).
Discussion
This analysis of two large cohorts of
extensively phenotyped ever-smokers
Table 2. Exacerbations
Retrospective Prospective
COPDGene SPIROMICS P Value COPDGene SPIROMICS P Value
Exacerbations, n 359 614 1,650 1,821
Exacerbation rate* 0.601 0.401 0.002 0.866 0.601 ,0.001
GOLD stage 1* 0.857 0.190 0.466 0.156 0.277 0.003
GOLD stage 2* 0.667 0.400 0.013 1.286 0.752 0.003
GOLD stage 3* 0.908 0.718 0.130 2.029 1.425 0.049
GOLD stage 4* 1.423 1.011 0.102 1.530 2.806 0.744
Healthy smoker exacerbation rate* 0.121 0.241 0.008 0.233 0.212 0.321
Severe exacerbations, n 98 238 479 565
Severe exacerbation rate* 0.164 0.155 0.746 0.251 0.189 0.005
GOLD stage 1* 0.0 0.085 0.015 0.125 0.082 0.545
GOLD stage 2* 0.135 0.135 0.999 0.341 0.192 0.033
GOLD stage 3* 0.223 0.270 0.487 0.579 0.514 0.356
GOLD stage 4* 0.535 0.571 0.820 0.670 0.998 0.930
Healthy smoker severe exacerbation rate* 0.029 0.077 0.052 0.041 0.057 0.985
Definition of abbreviations: COPDGene = Genetic Epidemiology of COPD; GOLD =Global Initiative for Chronic Obstructive Lung Disease; SPIROMICS =
Subpopulations and Intermediate Outcomes Measures in COPD Study.
*Exacerbation rate: calculated as number of exacerbations divided by number of patients and then adjusted for years of follow-up.
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without and with airflow obstruction
(SPIROMICS and COPDGene) used nearly
identical methodology to measure 90
plasma biomarkers and to determine their
associations with previous and future
respiratory events reported during careful
longitudinal follow-up. By comparing
results within the individual cohorts and in a
metaanalysis, we demonstrate two key
finding regarding blood biomarkers
obtained in the stable state: first, despite
statistically significant associations within a
given cohort or in metaanalysis of some
biomarkers with exacerbations
(independent of established clinical
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Figure 1. Scatter plot of P values for biomarkers. P values of each biomarker were plotted for the negative binomial regression using the model developed
with covariates as described in the METHODS section and without covariates. The dark lines represent P = 0.05. COPDGene =Genetic Epidemiology of
COPD; SPIROMICS = Subpopulations and Intermediate Outcomes Measures in COPD Study.
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predictors, including history of previous
exacerbation), that those associations
replicated poorly between cohorts; and
second, that biomarkers only marginally
improved the predictive value of easily
obtained clinical variables. Given the
magnitudes of follow-up (.6,300 person-
years), and of events, which among subjects
with COPD occurred in almost 60%
(any exacerbation) and 30% (severe
exacerbation), it is unlikely that these
findings reflect a lack of statistical power.
Instead, our results imply the need for
very considerable additional investigation
of the basic biology of exacerbations,
which these two studies recently showed
afflict not only those who meet current
definitions of COPD, but are also a feature
of some smokers without airflow
obstruction (29, 30).
These results provide a novel insight
into the shortcomings of the method by
which many previous studies attempted
to identify biomarkers predictive of
exacerbations. Although almost all
published work reported some positive
associations of biomarker with
exacerbations, some of these studies
reported biomarkers associated with
exacerbations (31, 32) or during recovery
(33), but few included validation in
independent cohorts and prospective
analysis of risk of future exacerbations, or
discussion of the effect size of individual
biomarkers. Each of these features is
addressed in the current study. Examples of
biomarkers associated with exacerbation risk
in previous studies include CRP, IL-6,
fibrinogen, white blood cell count, surfactant
protein D, chemokine (C-C motif) ligand 18
(PARC), CC16, and blood eosinophils
(34, 35). Most of these biomarkers were
identified in the ECLIPSE study, without
large-scale replication (1, 5, 6).
In agreement with previous studies, we
also identified several biomarkers associated
with a history of previous exacerbations.
Thus, inflammatory signatures likely remain
an important feature of subjects with COPD
who report exacerbations. However, we
extend the field by demonstrating how few
biomarkers, independent of clinical
variables, were predictive of the outcome of
future exacerbations. Moreover, those
biomarkers that we did identify in
SPIROMICS and COPDGene (e.g., DCN,
A2M, A1AT, sRAGE) differed from results
of ECLIPSE, even after creating subgroup
analyses to specifically replicate the
ECLIPSE cohort. Importantly, after
adjustment for key clinical covariates,
neither COPDGene nor SPIROMICS
identified fibrinogen as a predictive
biomarker of exacerbations. Nevertheless,
we confirmed the predictive value of clinical
variables (history of prior exacerbation,
dyspnea score, spirometry, and
gastroesophageal reflux disease), which
replicated significantly between our cohorts
to predict future exacerbations.
There are several possible reasons for
such discrepant results in the biomarker
field. One key candidate is the
heterogeneous nature of exacerbations,
which can be triggered by myriad factors.
Approximately half of exacerbations have
been associated with bacterial infections by
culture-dependent techniques and nearly
60% with viral infections (36), but some
exacerbations may be triggered by air
pollution (37), changes in temperature and
barometric pressure (38, 39), and possibly
shifts in intrapulmonary fluids in those
with occult heart failure (40). From this
viewpoint, the inability to identify
reproducible biomarkers follows inability to
classify the etiology for each exacerbation
accurately. Thus, with advances in
molecular diagnostics (e.g., NextGen
Sequencing, microbiome analysis) it may be
possible to subtype exacerbation triggers
more accurately, and accordingly, to find
biomarkers indicating susceptibility to
individual triggers. However, it is also
possible that no single or even combination
of plasma proteins measured in the stable
state will predict these highly stochastic
events. Thus, it may be necessary to develop
practical means to assess the function of cell
types within the lungs themselves,
especially airway epithelium and immune
cell types. An alternative would be to
examine the response of plasma biomarkers
to an evoked phenotype, or of blood cells to
stimulation ex vivo.
We considered potential factors that
might contribute to lack of reproducibility
between our cohorts, including differences
in clinical variables, such as current smoking
status, proportion of patients with
concurrent asthma, or geography. However,
the SPIROMICS and COPDGene cohorts
have many common features, including
their design, congruent follow-up methods,
and some (but not all) shared clinical sites at
which the same investigators recruit to both
studies. These two cohorts are generally
more similar to each other than to other
cohorts, including ECLIPSE, designed to
address different questions. Important
features of the current analysis are nearly
identical biomarker platform assessments,
adjustment for known clinical covariates,
and sufficient power (large number of
exacerbations). We are confident that the
populations and biomarker platforms were
comparable because a recent publication
showed nearly identical identification of
genetic markers for biomarkers (18).
Table 3. Negative Binomial Regression Severe Exacerbations (Prospective)
Biomarker
SPIROMICS COPDGene
b Coefficient P Value FDR b Coefficient P Value FDR
A2M 0.247 0.027 0.893 0.461 0.003 0.072
CCL16 20.047 0.599 0.914 0.317 0.043 0.348
CEACAM1 0.113 0.152 0.914 0.385 0.026 0.256
CXCL10 0.194 0.044 0.893 0.080 0.661 0.865
CXCL9 0.252 0.017 0.893 0.165 0.318 0.673
DCN 0.047 0.622 0.929 0.585 0.000 0.001
IgM 20.079 0.384 0.914 0.307 0.022 0.250
IL16 0.000 0.998 0.998 20.383 0.008 0.114
IL18BP 0.168 0.050 0.893 0.023 0.865 0.961
MDA_LDL_log* 0.057 0.865 0.985 0.838 0.039 0.348
MICA_log* 20.259 0.250 0.914 0.838 0.003 0.072
SERPINA1 20.030 0.743 0.929 0.521 0.001 0.061
SERPINE1 20.196 0.038 0.893 0.062 0.724 0.903
SLPI 20.055 0.561 0.914 20.317 0.019 0.246
SPINK1 0.118 0.160 0.914 20.333 0.006 0.101
Definition of abbreviations: COPDGene = Genetic Epidemiology of COPD; FDR = false discovery rate;
SPIROMICS = Subpopulations and Intermediate Outcomes Measures in COPD Study.
*Log denotes that variables were transformed to binary yes or no based on serum levels above or
below lower limit of quantitation of assay.
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Despite these strengths, there
remain limitations. Exacerbations were
reported at 3- or 6-month intervals and relied
on self-reporting. This method could lead to
underreporting of mild or moderate events,
but is unlikely to influence identification of
severe exacerbations (41). Because of our
follow-up design, we could not study the
seasonal nature of exacerbations. There are
statistical limitations (or strengths), such as
the requirement to adjust for multiple
comparisons using this large biomarker
panel. Additionally some biomarkers,
particularly low abundance interleukins,
such as IL-6, were below the limit of
detection in the RBM assays and required
analysis on other assay platforms. Most
importantly, neither cohort has detailed
information, such as viral or bacterial
respiratory cultures, or biomarker collection
during events.
In summary, this analysis identified
several biomarkers associated with
exacerbation history and exacerbation risk,
but there was poor reproducibility of
specific biomarkers between cohorts.
Ultimately, we show that clinical factors
remain the strongest current predictors of
future exacerbations. Improved clinical
utility of blood biomarkers to predict
COPD exacerbations awaits methodology
to reduce heterogeneity of events, possibly
by categorizing their triggers, and this may
not be attainable by testing in the stable
state. n
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